Tags

Type your tag names separated by a space and hit enter

Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
J Drug Target. 2010 Sep; 18(8):589-601.JD

Abstract

The treatment of ulcerative colitis (inflammatory bowel disease, IBD) has been achieved by using colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride. Chitosan microspheres were prepared separately for both the drugs using emulsion method followed by enteric coating with EudragitS-100. The in vitro drug release was investigated in different simulated GIT medium. The drug release in PBS (pH7.4) and simulated gastric fluid has shown almost similar pattern and rate, whereas a significant increase in drug release (70.3 +/- 1.36 and 72.5 +/- 1.33% of 5-ASA and Camylofine, respectively) was observed in medium containing 3% rat caecal matter, after 24 h. In control study, 57.1 +/- 1.13% of 5-ASA and 59.2 +/- 1.2% of Camylofine release was observed in 24 h. For enzyme induction, rats were orally administered with 1 mL of 1% w/v dispersion of chitosan for 5 days and release rate studies were conducted in SCF with 3% w/v of caecal matter. An enhanced drug release (i.e., 92.3 +/- 3.81 and 95.5 +/- 3.52% 5-ASA and Camylofine, respectively) was observed after 24 h in dissolution medium containing 3% caecal content obtained from enzyme induced animals. In vivo data showed that microspheres delivered most of its drug load (76.55 +/- 2.13%) to the colon after 9 h, which reflects its targeting potential to the colon. It is concluded that orally administered microspheres of both drugs can be used together for the specific delivery of drug to the colon and reduce symptoms of ulcerative colitis.

Authors+Show Affiliations

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, Sagar, MP, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20088681

Citation

Dubey, Rupal, et al. "Development and Characterization of Colon Specific Drug Delivery System Bearing 5-ASA and Camylofine Dihydrochloride for the Treatment of Ulcerative Colitis." Journal of Drug Targeting, vol. 18, no. 8, 2010, pp. 589-601.
Dubey R, Dubey R, Omrey P, et al. Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. J Drug Target. 2010;18(8):589-601.
Dubey, R., Dubey, R., Omrey, P., Vyas, S. P., & Jain, S. K. (2010). Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. Journal of Drug Targeting, 18(8), 589-601. https://doi.org/10.3109/10611860903572933
Dubey R, et al. Development and Characterization of Colon Specific Drug Delivery System Bearing 5-ASA and Camylofine Dihydrochloride for the Treatment of Ulcerative Colitis. J Drug Target. 2010;18(8):589-601. PubMed PMID: 20088681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. AU - Dubey,Rupal, AU - Dubey,Rounak, AU - Omrey,Pratibha, AU - Vyas,S P, AU - Jain,S K, PY - 2010/1/22/entrez PY - 2010/1/22/pubmed PY - 2010/12/16/medline SP - 589 EP - 601 JF - Journal of drug targeting JO - J Drug Target VL - 18 IS - 8 N2 - The treatment of ulcerative colitis (inflammatory bowel disease, IBD) has been achieved by using colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride. Chitosan microspheres were prepared separately for both the drugs using emulsion method followed by enteric coating with EudragitS-100. The in vitro drug release was investigated in different simulated GIT medium. The drug release in PBS (pH7.4) and simulated gastric fluid has shown almost similar pattern and rate, whereas a significant increase in drug release (70.3 +/- 1.36 and 72.5 +/- 1.33% of 5-ASA and Camylofine, respectively) was observed in medium containing 3% rat caecal matter, after 24 h. In control study, 57.1 +/- 1.13% of 5-ASA and 59.2 +/- 1.2% of Camylofine release was observed in 24 h. For enzyme induction, rats were orally administered with 1 mL of 1% w/v dispersion of chitosan for 5 days and release rate studies were conducted in SCF with 3% w/v of caecal matter. An enhanced drug release (i.e., 92.3 +/- 3.81 and 95.5 +/- 3.52% 5-ASA and Camylofine, respectively) was observed after 24 h in dissolution medium containing 3% caecal content obtained from enzyme induced animals. In vivo data showed that microspheres delivered most of its drug load (76.55 +/- 2.13%) to the colon after 9 h, which reflects its targeting potential to the colon. It is concluded that orally administered microspheres of both drugs can be used together for the specific delivery of drug to the colon and reduce symptoms of ulcerative colitis. SN - 1029-2330 UR - https://www.unboundmedicine.com/medline/citation/20088681/Development_and_characterization_of_colon_specific_drug_delivery_system_bearing_5_ASA_and_Camylofine_dihydrochloride_for_the_treatment_of_ulcerative_colitis_ L2 - http://www.tandfonline.com/doi/full/10.3109/10611860903572933 DB - PRIME DP - Unbound Medicine ER -